September - December 2005: 
Volume 18, Issue 3

Click on the image to download the Issue in PDF format.


Lung cancer: Immunosurveillance, immunoediting or immunoepigenetics?
Lung cancer is amongst the most frequent and malignant of neoplasms. Its mortality rates place it first of all types of cancer with more than 1.000.000 deaths annually worldwide. It is characterized by a series of biological and clinical features that position it in the epicenter of current research efforts. To this end, it is noted that this cancer responds poorly to various immunotherapeutic interventions as opposed to other malignancies.